News
Merck KGaA’s long courtship of SpringWorks Therapeutics has come to fruition as the German drugmaker has bought out the ...
With the American Association for Cancer Research’s annual conference now underway, oncology researchers can expect ...
Merck on Thursday said its first-quarter adjusted profit rose 7% as lower costs helped offset a 2% decline in sales, ...
Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...
Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc.
Domino’s Pizza reports earnings, Nvidia faces stiff competition in China, and Spirit AeroSystems finalizes a deal to transfer ...
Discover April's top dividend bargains! Explore high-quality blue-chip stocks like Merck & Schlumberger with strong yields, ...
Germany's Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology and rare disease business. The German ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback